iTeos Therapeutics, Inc. financial data

Symbol
ITOS on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
321 Arsenal Street, Bldg 312, Floor 3, Suite 301, Watertown, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 5, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.47K % -23.9%
Debt-to-equity 15 % +12.2%
Return On Equity -22.2 % -20.4%
Return On Assets -19.3 % -18.7%
Operating Margin -456 % +62%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 38.2M shares +6.56%
Common Stock, Shares, Outstanding 36.6M shares +2.04%
Entity Public Float 494M USD
Common Stock, Value, Issued 37K USD +2.78%
Weighted Average Number of Shares Outstanding, Basic 40.5M shares +13.2%
Weighted Average Number of Shares Outstanding, Diluted 40.5M shares +13.2%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 35M USD +178%
Research and Development Expense 145M USD +28.4%
General and Administrative Expense 49.1M USD -2.61%
Operating Income (Loss) -160M USD -5.58%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -120M USD -10.4%
Income Tax Expense (Benefit) 14.1M USD +290%
Net Income (Loss) Attributable to Parent -134M USD -19.3%
Earnings Per Share, Basic -3.32 USD/shares -5.4%
Earnings Per Share, Diluted -3.32 USD/shares -5.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 142M USD -43.4%
Assets, Current 510M USD -7.47%
Property, Plant and Equipment, Net 4.9M USD +4.24%
Operating Lease, Right-of-Use Asset 5.09M USD -15.7%
Other Assets, Noncurrent 894K USD +1.25%
Assets 687M USD +2.9%
Accounts Payable, Current 8.5M USD -24.7%
Employee-related Liabilities, Current 10.1M USD +18.3%
Accrued Liabilities, Current 943K USD -95.7%
Liabilities, Current 40.4M USD +0.87%
Operating Lease, Liability, Noncurrent 3.76M USD -21.8%
Liabilities 96.7M USD +4.68%
Accumulated Other Comprehensive Income (Loss), Net of Tax -16M USD -20.8%
Retained Earnings (Accumulated Deficit) -9.78M USD -108%
Stockholders' Equity Attributable to Parent 590M USD +2.62%
Liabilities and Equity 687M USD +2.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -32.4M USD -22%
Net Cash Provided by (Used in) Financing Activities 22K USD -96.2%
Net Cash Provided by (Used in) Investing Activities -69.6M USD -120%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 36.6M shares +2.04%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -105M USD -75.9%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 142M USD -43.4%
Deferred Tax Assets, Valuation Allowance 97.3M USD +30.8%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 99.3M USD +30.2%
Operating Lease, Liability 5.1M USD -15.9%
Payments to Acquire Property, Plant, and Equipment 945K USD +694%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -137M USD -18%
Lessee, Operating Lease, Liability, to be Paid 5.56M USD -16.9%
Property, Plant and Equipment, Gross 9.81M USD +8.07%
Operating Lease, Liability, Current 1.34M USD +6.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.52M USD +3.47%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.55M USD +3.53%
Operating Lease, Weighted Average Discount Rate, Percent 0.05 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 468K USD -26.9%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.02M USD -28.7%
Deferred Tax Assets, Operating Loss Carryforwards 17.8M USD -18.2%
Unrecognized Tax Benefits 46.7M USD +14.1%
Lessee, Operating Lease, Liability, to be Paid, Year Four 843K USD -10.4%
Operating Lease, Payments 1.54M USD +28%
Additional Paid in Capital 616M USD +32.8%
Deferred Tax Assets, Net of Valuation Allowance 1.95M USD +5.59%
Share-based Payment Arrangement, Expense 29.9M USD +10.8%